Anti-Human CD194 (CCR4) (Mogamulizumab) Fc Muted HRP
|Amount :||100 µg|
|Isotype :||Human IgG1k|
|Content :||Concentration : 0.5 mg/ml
This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
|Storage condition :||This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.|
|Alternative Name :||CD194; CKR-4; CCR-4; CCR4; K5-5|
|Immunogen Information :||Humanization of mouse anti-CCR4 mAb7.|
Expression Host : HEK-293
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only.
Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1infected cells and the levels of inflammatory markers related to HTLV-1Associated Myelopathy.3
The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA
For Research Use Only. Not for use in diagnostic/therapeutics procedures.